Skip to content

Our Approach

George Medicines is not a traditional drug development company. We take existing best-in-class existing treatments and formulate combinations of them into a single pill. These are intended to provide the optimal balance of high efficacy and improved safety, with potential for significant improvements in clinical outcomes and long-term adherence to treatment.

No.2 Fact

According to the World Health Organization, only 50% of patients in developed countries who suffer from chronic diseases adhere to treatment recommendations. In developing countries, when taken together with poor access to health care, lack of appropriate diagnosis and limited access to medicines, poor adherence is threatening any effort to tackle chronic conditions such as hypertension.

Reference Link CLICK HERE

Fixed-dose combinations for non-communicable diseases

George Medicines’ drug development programmes target non-communicable diseases (NCDs), the world’s leading causes of death and disability. Our novel, fixed, ultra-low dose combinations would reduce the need for patients to take multiple sets of pills daily and offer the potential for improvements in medication adherence.

No.3 Fact

NCDs are responsible for 71 percent of global deaths annually, and 15 million people who die from NCDs are between 30 and 69 years old, according to Access Accelerated, and most of these are in low- and middle-income countries. These premature deaths during their most economically productive years have a significant economic impact on these countries.

Reference Link CLICK HERE

Affordability & Accessibility

By designing affordable treatments in a single pill, George Medicines is looking to make a socio-economic impact on patients’ lives as well as helping them to live better and longer. We strive to make better treatments for all.

Our partners know the local markets and populations well, so that we can get our medicines to the patients who need them in the most affordable way.

The George Medicines Business Model

Research from The George Institute

Optimal product selection & IP protection

Formulation development

Late stage clinical development & registration in key territories